LUND, Sweden, Sept. 30, 2022 /PRNewswire/ — Hansa Biopharma AB (NASDAQ Stockholm: HNSA) will publish its interim report for January-September 2022 at 8:00 a.m. CET on October 20, 2022. All interested parties are invited to participate in a conference call, which will include a presentation of the interim results and a business update, on the same date at 2:00 p.m. CET/8:00 a.m. EST. The event will be moderated by Hansa Biopharma CEO Søren Tulstrup and CFO Donato Spota and the presentation will be in English.

The slides used in the presentation will be streamed live on the company’s website during the call under “Events and Presentations” and will also be made available online after the call. Link to presentation

To join the conference call, please use the login information provided below:

Sweden: +46 10 884 80 16

UK: +44 020 3936 2999

USA: +1 646 664 1960

Participant access code: 178360

The webcast will be available on https://streams.eventcdn.net/hansa/interim-report-for-january-september-2022/

Financial calendar and updated events 2022/2023

October 12, 2022 HC Wainwright KOL Expert Call on Anti-GBM Disease (Virtual)

Oct. 20, 2022 Interim report from January to September 2022

Oct 20, 2022 Redeye After Work Presentation, Gothenburg

Oct 21, 2022 Redeye Lunch presentation, Stockholm

October 26, 2022 Økonomisk Ugebrev Life Science Conference, Copenhagen

Oct 27, 2022 HCA Capital Expert call on the commercial progress and launch strategy (virtual)

Nov 22, 2022 Bryan Garnier KOL Call for Kidney Transplant Experts (Virtual)

Nov 23, 2022 SEB Healthcare Seminar 2022, Stockholm

November 24, 2022 Redeye Life Science Day, Stockholm

1 Dec. 2022 Erik Penser Banks Temadag – Healthcare, Stockholm

December 7, 2022 North American Life Sciences Conference in New York

December 15, 2022 DNB Nordic Healthcare Conference, Oslo

January 9, 2023 JPM Week, San Francisco

March 14, 2023 Carnegie Nordic Healthcare Seminar 2023, Stockholm

For more information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
Email: [email protected]

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company whose mission is to develop and commercialize innovative, life-saving and life-changing treatments for patients with rare immunological diseases. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleavage enzyme therapy, which has been shown to enable renal transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and operates in Europe and the United States. The company is listed on Nasdaq Stockholm under the symbol HNSA. Learn more about www.hansabiopharma.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-september-2022-and-bu, c3640225

The following files are available for download:

Show original content:https://www.prnewswire.com/news-releases/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-september-2022-and-business-update-301637644. html

SOURCE Hansa Biopharma AB

Company Codes: Bloomberg: [email protected], ISIN: SE0002148817, RICS: HNSA.ST, Stockholm: HNSA